Abstract

Secondary resistance to bromocriptine and cabergoline therapy in hyperprolactinemia: One case of pregnancy with IVF-ET

Highlights

  • Prolactin (PRL) is an important hormone involved in regulating the gonadal axis

  • While the mechanism of secondary resistance remains unknown and not possible to predict, the woman can become pregnant after IVF-ET, even if the PRL level remains higher than normal

  • We describe a very rare case of a 32-year-old woman with unexplained hyperprolactinemia, who following 1 year of almost complete anti-secretory response dopamine agonist therapy first with bromocriptine, developed secondary resistance to bromocriptine and cabergoline

Read more

Summary

Conclusion

We described a rare case of a 32-year-old woman with unexplained hyperprolactinemia who developed secondary dopamine agonist resistance following 1 years of DA therapy. As the underlying mechanism is unknown, patients who wish to become pregnant should be advised to reduce mental stress, and treatment may be given to reduce PRL levels to restore ovulation. Ovulation induction and assisted reproductive therapy may be given as necessary to facilitate pregnancy. Once the patient becomes pregnant, the dose of the dopamine agonist should be tapered as soon as possible to minimize its effect on the fetus

Introduction
Discussion
Findings
Availability of data and materials
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call